Prescription Drug Pricing: Background, Discount Programs and Cost Lowering Strategies

Elias B. Toft (Editor)

Series: Pharmacology – Research, Safety Testing and Regulation
BISAC: MED072000

Clear

$95.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Chapter 1 examines the actions of drug companies in raising prescription drug prices in the United States, as well as the effects of these actions on the Federal and state budgets, and on American families.

Chapter 2 addresses frequently asked questions about government and private-sector policies that affect drug prices and availability. Among the prescription drug topics covered are federally funded research and development, regulation of direct-to-consumer advertising, legal restrictions on reimportation, and federal price negotiation.

The 340B Drug Pricing Program requires drug manufacturers to sell outpatient drugs at discounted prices to covered entities—eligible clinics, hospitals, and others—in order to have their drugs covered by Medicaid. Covered entities are only allowed to provide 340B drugs to certain eligible patients. Chapter 3 reviews the Health Resources and Services Administration’s (HRSA) oversight of the 340B Program to ensure compliance with program rules.

In 2017, nearly 60% of U.S. adults aged 18–64 reported being prescribed medication in the past 12 months. Approximately 70% of prescription medications carry out-of-pocket costs. Strategies to reduce prescription drug costs at the individual level are discussed in chapters 4 and 5.

Each year, Americans pay more for prescription drugs, and rising drug prices have a disproportionate impact on older Americans. Chapter 6 examines the history of rising drug prices for the brand-name drugs most commonly prescribed for seniors.

Generic drugs—copies of brand-name drugs—lead to significant cost savings. Before a generic drug can be marketed, FDA must approve the generic drug application. According to FDA, applications go through an average of three cycles of review before being approved, which may take years. Chapter 7 examines 1) the first review cycle approval rate of generic drug applications in recent years and factors that may have contributed to whether applications were approved; and 2) changes FDA has made to increase the first review cycle approval rate.
(Imprint: SNOVA)

Preface

Chapter 1. Examining the Actions of Drug Companies in Raising Prescription Drug Prices

Chapter 2. Frequently Asked Questions About Prescription Drug Pricing and Policy
Suzanne M. Kirchhoff, Susan Thaul and Judith A. Johnson

Chapter 3. Drug Discount Program: Status of Agency Efforts to Improve 340B Program Oversight
Debra A. Draper

Chapter 4. Strategies Used by Adults Aged 18–64 to Reduce Their Prescription Drug Costs, 2017
Robin A. Cohen, Ph.D., Peter Boersma, M.P.H., and Anjel Vahratian, Ph.D., M.P.H.

Chapter 5. Strategies Used by Adults Aged 65 and Over to Reduce Their Prescription Drug Costs, 2016–2017
Robin A. Cohen, Ph.D., and Peter Boersma, M.P.H.

Chapter 6. Manufactured Crisis: How Devastating Drug Price Increases Are Harming America’s Seniors
U.S. Senate Homeland Security & Governmental Affairs Committee, Minority Office

Chapter 7. Generic Drug Applications: FDA Should Take Additional Steps to Address Factors That May Affect Approval Rates in the First Review Cycle

Index

You have not viewed any product yet.


SHOW ALL OF MY RECENTLY VIEWED BOOKS